Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats

Journal of Pineal Research

Volumn 52, Issue 1, 2012, Pages 128-137

  Sae Ung, Kwankanit ^a   Uéda, Kenji ^b   Govitrapong, Piyarat ^c,d   Phansuwan Pujito, Pansiri ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c MAHIDOL UNIVERSITY   (Thailand)

^d NONE   (Thailand)

Author keywords

alpha synuclein; amphetamine; dopaminergic pathway; melatonin; postnatal rat

Indexed keywords

ALPHA SYNUCLEIN; AMPHETAMINE; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSOL; DOPAMINERGIC NERVE CELL; DRUG SCREENING; FEMALE; IMMUNOREACTIVITY; NERVE ENDING; NEWBORN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PERIKARYON; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA;

EID: 83555174870     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00927.x     Document Type: Article

References (54)

1. Mori F, Tanji K, Yoshimoto M, et al., Demonstration of α-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 2002; 176: 98-104. (Pubitemid 34762109)
2. Fornai F, Lenzi P, Ferrucci M, et al., Occurrence of neuronal inclusions combined with increased nigral expression of α-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res Bull 2005; 65: 405-413.
3. Yu S, Li X, Liu G, et al., Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007; 145: 539-555. (Pubitemid 46350815)
4. Yu S, Uéda K, Chan P,. α-Synuclein and dopamine metabolism. Mol Neurobiol 2005; 31: 243-254.
5. Schuiz-Schaeffer W,. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120: 131-143.
6. Mccormack A, Di Monte D,. Enhanced α-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. Curr Protein Pept Sci 2009; 10: 476-482.
7. Ma Q-L, Chan P, Yoshi M, et al., α-synuclein aggregation and neurodegenerative diseases. J Alzheimers Dis 2003; 5: 139-148.
8. Maguire-Zeiss KA, Short DW, Federoff HJ,. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res Mol Brain Res 2005; 134: 18-23. (Pubitemid 40409494)
9. Kim S, Seo JH, Suh YH,. α-Synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism Relat Disord 2004; 10: S9-S13.
10. Xu S, Zhou M, Yu S, et al., Oxidative stress induces nuclear translocation of C-terminus of α-synuclein in dopaminergic cells. Biochem Biophys Res Commun 2006; 342: 330-335. (Pubitemid 43247395)
11. Kuczenski R, Segal D, Cho A, et al., Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995; 15: 1308-1317.
12. Champney TH, Matthews RT,. Pineal serotonin is resistant to depletion by serotonergic neurotoxins in rats. J Pineal Res 1991; 11: 163-167.
13. Manzana EJ, Chen WJ, Champney TH,. Acute melatonin and para-chloroamphetamine interactions on pineal, brain and serum serotonin levels as well as stress hormone levels. Brain Res 2001; 909: 127-137. (Pubitemid 32710126)
14. Davison C, Gow AJ, Lee TH, et al., Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 2001; 36: 1-22. (Pubitemid 32763126)
15. Ajjimaporn A, Swinscoe J, Shavali S, et al., Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells. Brain Res Bull 2005; 67: 466-475. (Pubitemid 41416741)
16. Klongpanichapak S, Phansuwan-Pujito P, Ebadi M, et al., Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. J Pineal Res 2007; 43: 65-73. (Pubitemid 47035223)
17. Klongpanichapak S, Phansuwan-Pujito P, Ebadi M, et al., Melatonin inhibits amphetamine-induced increase in α-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells. Neurosci Lett 2008; 436: 309-313.
18. Wissessmith W, Phansuwan-Pujito P, Govitrapong P, et al., Melatonin reduces induction of Bax, caspase and cell death in methamphetamine-treated human neuroblastoma SH-SY5Y cultured cells. J Pineal Res 2009; 46: 433-440.
19. Suwanjang W, Phansuwan-Pujito P, Govitrapong P, et al., The protective effect of melatonin on methamphetamine-induced calpain-dependent death pathway in human neuroblastoma SH-SY5Y cultured cells. J Pineal Res 2010; 48: 94-101.
20. Kaewsuk S, Sae-ung K, Phansuwan-Pujito P, et al., Melatonin attenuates methamphetamine-induced reduction of tyrosine hydroxylase, synaptophysin and growth-associated protein-43 levels in the neonatal rat brain. Neurochem Int 2009; 55: 397-405.
21. Tan D-X, Chen LD, Poeggeler B, et al., Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1: 57-60.
22. Reiter RJ, Tan D-X, Gitto E, et al., Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol 2004; 56: 159-170. (Pubitemid 38931382)
23. Reiter RJ, Paredes SD, Manchester LC, et al., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
24. Korkmaz A,. Epigenetic actions of melatonin. J Pineal Res 2009; 46: 117-118.
25. Hardeland R, Tan DX, Reiter RJ,. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
26. Mayo JC, Sainz RM, Antolín I, et al., Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 2002; 59: 1706-1713. (Pubitemid 35346974)
27. Rodriguez C, Mayo JC, Sainz RM, et al., Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9. (Pubitemid 38130283)
28. Acuna-Castroviejo D, Escames G, Leon J, et al., Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003; 527: 549-557. (Pubitemid 38197684)
29. Paradies G, Petrosillo G, Paradies V, et al., Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
30. Menendez-Pelaez A, Reiter RJ,. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res 1993; 15: 59-69. (Pubitemid 24028611)
31. Wells PG, Kim PM, Laposa RR, et al., Oxidative damage in chemical teratogenesis. Mutat Res 1997; 396: 65-78. (Pubitemid 28012643)
32. Mauceli G, Busceti CI, Pellegrini A, et al., Overexpression of α-synuclein following methamphetamine: is it good or bad? Ann N Y Acad Sci 2006; 1074: 191-197. (Pubitemid 44532824)
33. Uéda K, Fukushima H, Masliah E, et al., Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 11282-11286. (Pubitemid 23354413)
34. Arima K, Uéda K, Sunohara N, et al., Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998; 808: 93-100. (Pubitemid 29003204)
35. Ajjimaporn A, Phansuwan-Pujito P, Ebadi M, et al., Zinc protects SK-N-SH cells from methamphetamine-induced α-synuclein expression. Neurosci Lett 2007; 419: 59-63. (Pubitemid 46711138)
36. Fornai F, Lenzi P, Gesi M, et al., Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem 2004; 88: 114-123. (Pubitemid 38030214)
37. Sangchot P, Sharma S, Chetsawang B, et al., Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci 2002; 24: 143-153. (Pubitemid 36151444)
38. Ahn B-H, Rhim H, Kim SY, et al., α-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 Cells. J Biol Chem 2002; 277: 12334-12342. (Pubitemid 34952804)
39. Sharon R, Goldberg MS, Bar-Josef I, et al., α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci USA 2001; 98: 9110-9115. (Pubitemid 32743877)
40. Cubells J, Rayport S, Rajendran G, et al., Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 1994; 14: 2260-2271. (Pubitemid 24108131)
41. Bisaglia M, Greggio E, Maric D, et al., α-Synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci 2010; 11: 41.
42. Conway KA, Rochet J-C, Bieganski RM, et al., Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 2001; 294: 1346-1349. (Pubitemid 33063102)
43. Rochet J-C, Fleming Outeiro T, Conway K, et al., Interactions among α-synuclein, dopamine, and biomembranes. J Mol Neurosci 2004; 23: 23-33.
44. Caughey B, Lansbury PT,. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267-298. (Pubitemid 37064935)
45. Iacovelli L, Fulceri F, De Blasi A, et al., The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders. Exp Neurol 2006; 201: 24-31. (Pubitemid 44223465)
46. Kish SJ, Shannak K, Hornykiewicz O,. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-880. (Pubitemid 18090271)
47. Braak H, Ghebremedhin E, Rüb U, et al., Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134. (Pubitemid 39362633)
48. Grant RJ, Clarke PBS,. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: effect of hypothermia. Neuroscience 2002; 115: 1281-1294. (Pubitemid 35351715)
49. German DC, Dubach M, Askari S, et al., 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 1988; 24: 161-174. (Pubitemid 18044250)
50. Mosharov EV, Larsen KE, Kanter E, et al., Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 2009; 62: 218-229.
51. Maingay M, Romeo-Ramos M, Carta M, et al., Ventral tegmental area dopamine neurons are resistant to human mutant α-synuclein overexpression. Neurobiol Dis 2006; 23: 522-532. (Pubitemid 44251282)
52. Nopparat C, Porter JE, Ebadi M, et al., The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy. J Pineal Res 2010; 49: 382-389.
53. Benήtez-King G, Rήos A, Martήnez A, et al., In vitro inhibition of Ca2+/calmodulin-dependent kinase II activity by melatonin. Biochim Biophys Acta 1996; 1290: 191-196.
54. Jimenez-Jorge S, Guerrero JM, Jimenez-Caliani AJ, et al., Evidence for melatonin synthesis in the rat brain during development. J Pineal Res 2007; 42: 240-246. (Pubitemid 46365060)